Cargando…

Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis

BACKGROUND: Patients with multiple sclerosis receiving ocrelizumab-treatment are in desperate need of a protection against SARS-CoV-2 infection. METHODS: In this study, Euroimmun semi-quantitative Anti-SARS-CoV-2 IgG for detection of humoral response and ELISpot assays for detection of SARS-CoV-2-sp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pompsch, Mosche, Fisenkci, Neslinur, Horn, Peter A., Kraemer, Markus, Lindemann, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606235/ https://www.ncbi.nlm.nih.gov/pubmed/34802469 http://dx.doi.org/10.1186/s42466-021-00158-5

Ejemplares similares

Cellular and Humoral Immunity after the Third Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplant Recipients
por: Thümmler, Laura, et al.
Publicado: (2022)

Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients
por: Lindemann, Monika, et al.
Publicado: (2021)

Cellular and Humoral Immunity against Different SARS-CoV-2 Variants Is Detectable but Reduced in Vaccinated Kidney Transplant Patients
por: Thümmler, Laura, et al.
Publicado: (2022)

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine
por: Čiučiulkaitė, Ieva, et al.
Publicado: (2022)

Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment
por: Thümmler, Laura, et al.
Publicado: (2022)

Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab
por: Katz, J.D., et al.
Publicado: (2022)

Proteinase-3-(cANCA)-assoziierte Colitis ulcerosa mit möglicher entzündlicher leukenzephalopathischer ZNS‑Beteiligung
por: Pompsch, Mosche, et al.
Publicado: (2020)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab
por: Groß-Albenhausen, Elina, et al.
Publicado: (2023)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
por: Gibson, Elena G, et al.
Publicado: (2021)

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
por: Hauser, Stephen L., et al.
Publicado: (2020)

Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients
por: Georgieva, Zoya G, et al.
Publicado: (2021)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022)

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience
por: S., Guerrieri, et al.
Publicado: (2021)

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
por: Suwanwongse, Kulachanya, et al.
Publicado: (2020)

Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
por: Pedotti, Rosetta, et al.
Publicado: (2021)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
por: Tazza, F., et al.
Publicado: (2021)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

Persistent SARS-CoV-2 Infection in a Multiple Sclerosis Patient on Ocrelizumab: A Case Report
por: Ambadapoodi, Raghava S., et al.
Publicado: (2023)

Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab
por: Nytrova, Petra, et al.
Publicado: (2023)

Ocrelizumab: SARS-CoV-2 pneumonia: 2 case reports
Publicado: (2020)

Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies
por: Feng, Jenny J, et al.
Publicado: (2017)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study
por: Kister, Ilya, et al.
Publicado: (2022)

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
por: Weberpals, Janick, et al.
Publicado: (2022)

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
por: Iannetta, Marco, et al.
Publicado: (2020)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study
por: Conte, William L.
Publicado: (2021)

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
por: Seery, Nabil, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3i53j1sdj9ggt22vd1phagkhr1